News
Stay up to date with CellCentric and follow us on Twitter
Key information, updates and news can be found through our tweets
Listening to patient preferences is important to developing real-world new multiple myeloma treatments. iPREFER study: https://clinicaltrials.gov/study/NCT06322927 @TheChristieNHS
FDA and International Myeloma Society mtg: Instead of prior lines of therapy, it’s useful to assess patients by drug class refractory state.
There is a growing population in multiple myeloma that can benefit from therapeutic options that can be delivered in an outpatient community setting.
Listening to patient preferences is important to developing real-world new multiple myeloma treatments. iPREFER study: https://clinicaltrials.gov/study/NCT06322927 @TheChristieNHS
FDA and International Myeloma Society mtg: Instead of prior lines of therapy, it’s useful to assess patients by drug class refractory state.
There is a growing population in multiple myeloma that can benefit from therapeutic options that can be delivered in an outpatient community setting.
We continue to advance our pioneering oral p300/CBP inhibitor in Phase II. Inobrodib gets to the heart of progressing multiple myeloma by impacting MYC and IRF4.
Post advanced therapies, there is a growing need for all oral myeloma treatments. Inobrodib +pom+dex highly effective late/last line (ASH 23) https://lnkd.in/eEZwDAPt
Looking forward to the FDA-IMS meeting. We continue to advance our novel oral drug, inobrodib. Targeting p300/CBP: displacing not degrading. See: https://www.eventcreate.com/e/fda-ims-joint-workshop2024
Listening to patient preferences is important to developing real-world new multiple myeloma treatments. iPREFER study: https://clinicaltrials.gov/study/NCT06322927 @TheChristieNHS
FDA and International Myeloma Society mtg: Instead of prior lines of therapy, it’s useful to assess patients by drug class refractory state.
There is a growing population in multiple myeloma that can benefit from therapeutic options that can be delivered in an outpatient community setting.
We continue to advance our pioneering oral p300/CBP inhibitor in Phase II. Inobrodib gets to the heart of progressing multiple myeloma by impacting MYC and IRF4.
Post advanced therapies, there is a growing need for all oral myeloma treatments. Inobrodib +pom+dex highly effective late/last line (ASH 23) https://lnkd.in/eEZwDAPt
Looking forward to the FDA-IMS meeting. We continue to advance our novel oral drug, inobrodib. Targeting p300/CBP: displacing not degrading. See: https://www.eventcreate.com/e/fda-ims-joint-workshop2024
Listening to patient preferences is important to developing real-world new multiple myeloma treatments. iPREFER study: https://clinicaltrials.gov/study/NCT06322927 @TheChristieNHS
FDA and International Myeloma Society mtg: Instead of prior lines of therapy, it’s useful to assess patients by drug class refractory state.
There is a growing population in multiple myeloma that can benefit from therapeutic options that can be delivered in an outpatient community setting.
We continue to advance our pioneering oral p300/CBP inhibitor in Phase II. Inobrodib gets to the heart of progressing multiple myeloma by impacting MYC and IRF4.
Post advanced therapies, there is a growing need for all oral myeloma treatments. Inobrodib +pom+dex highly effective late/last line (ASH 23) https://lnkd.in/eEZwDAPt
Looking forward to the FDA-IMS meeting. We continue to advance our novel oral drug, inobrodib. Targeting p300/CBP: displacing not degrading. See: https://www.eventcreate.com/e/fda-ims-joint-workshop2024
Latest press releases